Top

Published in:

01-06-2010

Matricellular proteins: from homeostasis to inflammation, cancer, and metastasis

Authors: Claudia Chiodoni, Mario P. Colombo, Sabina Sangaletti

Published in: Cancer and Metastasis Reviews | Issue 2/2010

Abstract

The family of matricellular proteins comprises molecules with disparate biology. The main characteristic of matricellular proteins is to be expressed during tissue renewal and repair in order to “normalize” the tissue. Tumors are wound that do not heal, and tumor growth and metastasis can be viewed as a consequence of aberrant homeostasis, during which matricellular proteins are often upregulated. In the tumor microenvironment, they can be produced by both tumor cells and surrounding stromal cells, such as fibroblasts and macrophages. In this context, matricellular proteins can exert several functions that actively contribute to tumor progression. They may (a) regulate cellular adhesion and migration and extracellular matrix deposition, (b) control tumor infiltration by macrophages or other leukocytes, (c) affect tumor angiogenesis, (d) regulate TGFβ and other growth factor receptor signals, (e) directly stimulate integrin receptors to transduce pro-survival or pro-migratory signals, and (f) regulate the wnt/β-catenin pathways. Most of these functions contribute to settle a chronic low inflammatory state, whose involvement in tissue transformation and tumor progression is now established.

Joyce, J. A., & Pollard, J. W. (2009). Microenvironmental regulation of metastasis. Nature Reviews Cancer, 9, 239–252.PubMedCrossRef

Sangaletti, S., & Colombo, M. P. (2008). Matricellular proteins at the crossroad of inflammation and cancer. Cancer Letters, 267, 245–253.PubMedCrossRef

Bornstein, P. (2009). Matricellular proteins: an overview. Journal of Cell Communication Signal, 3(3–3), 163–165.CrossRef

Yang, Z., Kyriakides, T. R., & Bornstein, P. (2000). Matricellular proteins as modulators of cell-matrix interactions: adhesive defect in thrombospondin 2-null fibroblasts is a consequence of increased levels of matrix metalloproteinase-2. Molecular Biology of the Cell, 11, 3353–3364.PubMed

Yan, Q., Weaver, M., Perdue, N., & Sage, E. H. (2005). Matricellular protein SPARC is translocated to the nuclei of immortalized murine lens epithelial cells. Journal of Cell Physiology, 203, 286–294.CrossRef

Perbal, B. (2006). New insight into CCN3 interactions—nuclear CCN3: fact or fantasy? Cell Communication Signal, 4, 6.CrossRef

Fisher, L. W., Torchia, D. A., Fohr, B., Young, M. F., & Fedarko, N. S. (2001). Flexible structures of SIBLING proteins, bone sialoprotein, and osteopontin. Biochemical and Biophysical Research Communications, 280, 460–465.PubMedCrossRef

Senger, D. R., Wirth, D. F., & Hynes, R. O. (1979). Transformed mammalian cells secrete specific proteins and phosphoproteins. Cell, 16, 885–893.PubMedCrossRef

Ashkar, S., Weber, G. F., Panoutsakopoulou, V., Sanchirico, M. E., Jansson, M., Zawaideh, S., et al. (2000). Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science, 287, 860–864.PubMedCrossRef

10.

O'Regan, A. W., Nau, G. J., Chupp, G. L., & Berman, J. S. (2000). Osteopontin (Eta-1) in cell-mediated immunity: teaching an old dog new tricks. Immunology Today, 21, 475–478.PubMedCrossRef

11.

Weiss, J. M., Renkl, A. C., Maier, C. S., Kimmig, M., Liaw, L., Ahrens, T., et al. (2001). Osteopontin is involved in the initiation of cutaneous contact hypersensitivity by inducing Langerhans and dendritic cell migration to lymph nodes. Journal of Experimental Medicine, 194, 1219–1229.PubMedCrossRef

12.

El-Tanani, M. K. (2008). Role of osteopontin in cellular signaling and metastatic phenotype. Frontiers in Bioscience, 13, 4276–4284.PubMedCrossRef

13.

El-Tanani, M. K., Campbell, F. C., Kurisetty, V., Jin, D., McCann, M., & Rudland, P. S. (2006). The regulation and role of osteopontin in malignant transformation and cancer. Cytokine and Growth Factor Reviews, 17, 463–474.PubMedCrossRef

14.

Rittling, S. R., & Chambers, A. F. (2004). Role of osteopontin in tumour progression. British Journal of Cancer, 90, 1877–1881.PubMedCrossRef

15.

Wai, P. Y., & Kuo, P. C. (2008). Osteopontin: regulation in tumor metastasis. Cancer and Metastasis Reviews, 27, 103–118.PubMedCrossRef

16.

Tuck, A. B., O'Malley, F. P., Singhal, H., Harris, J. F., Tonkin, K. S., Kerkvliet, N., et al. (1998). Osteopontin expression in a group of lymph node negative breast cancer patients. International Journal of Cancer, 79, 502–508.CrossRef

17.

Chambers, A. F., Wilson, S. M., Kerkvliet, N., O'Malley, F. P., Harris, J. F., & Casson, A. G. (1996). Osteopontin expression in lung cancer. Lung Cancer, 15, 311–323.PubMedCrossRef

18.

Thalmann, G. N., Sikes, R. A., Devoll, R. E., Kiefer, J. A., Markwalder, R., Klima, I., et al. (1999). Osteopontin: possible role in prostate cancer progression. Clinical Cancer Research, 5, 2271–2277.PubMed

19.

Yeatman, T. J., & Chambers, A. F. (2003). Osteopontin and colon cancer progression. Clinical & Experimental Metastasis, 20, 85–90.CrossRef

20.

Furger, K. A., Menon, R. K., Tuck, A. B., Bramwell, V. H., & Chambers, A. F. (2001). The functional and clinical roles of osteopontin in cancer and metastasis. Current Molecular Medicine, 1, 621–632.PubMedCrossRef

21.

Fedarko, N. S., Jain, A., Karadag, A., Van Eman, M. R., & Fisher, L. W. (2001). Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clinincal Cancer Research, 7, 4060–4066.

22.

Singhal, H., Bautista, D. S., Tonkin, K. S., O'Malley, F. P., Tuck, A. B., Chambers, A. F., et al. (1997). Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clinical Cancer Research, 3, 605–611.PubMed

23.

Bramwell, V. H., Doig, G. S., Tuck, A. B., Wilson, S. M., Tonkin, K. S., Tomiak, A., et al. (2006). Serial plasma osteopontin levels have prognostic value in metastatic breast cancer. Clinical Cancer Research, 12, 3337–3343.PubMedCrossRef

24.

Wu, C. Y., Wu, M. S., Chiang, E. P., Wu, C. C., Chen, Y. J., Chen, C. J., et al. (2007). Elevated plasma osteopontin associated with gastric cancer development, invasion and survival. Gut, 56, 782–789.PubMedCrossRef

25.

Chakraborty, G., Jain, S., Behera, R., Ahmed, M., Sharma, P., Kumar, V., et al. (2006). The multifaceted roles of osteopontin in cell signaling, tumor progression and angiogenesis. Current Molecular Medicine, 6, 819–830.PubMedCrossRef

26.

Bramwell, V. H., Tuck, A. B., Wilson, S. M., Stitt, L. W., Cherian, A. K., Rorke, S. C., et al. (2005). Expression of osteopontin and HGF/met in adult soft tissue tumors. Cancer Biology and Therapy, 4, 1336–1341.PubMed

27.

Tuck, A. B., Elliott, B. E., Hota, C., Tremblay, E., & Chambers, A. F. (2000). Osteopontin-induced, integrin-dependent migration of human mammary epithelial cells involves activation of the hepatocyte growth factor receptor (Met). Journal of Cellular Biochemistry, 78, 465–475.PubMedCrossRef

28.

Tuck, A. B., Hota, C., Wilson, S. M., & Chambers, A. F. (2003). Osteopontin-induced migration of human mammary epithelial cells involves activation of EGF receptor and multiple signal transduction pathways. Oncogene, 22, 1198–1205.PubMedCrossRef

29.

Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008). Cancer-related inflammation. Nature, 454, 436–444.PubMedCrossRef

30.

Pollard, J. W. (2008). Macrophages define the invasive microenvironment in breast cancer. Journal Leukocyte Biology, 84, 623–630.CrossRef

31.

Psaila, B., Kaplan, R. N., Port, E. R., & Lyden, D. (2006). Priming the 'soil' for breast cancer metastasis: the pre-metastatic niche. Breast Disease, 26, 65–74.PubMed

32.

Yang, L., Huang, J., Ren, X., Gorska, A. E., Chytil, A., Aakre, M., et al. (2008). Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell, 13, 23–35.PubMedCrossRef

33.

Lund, S. A., Giachelli, C. M., & Scatena, M. (2009). The role of osteopontin in inflammatory processes. Journal Cell Communication Signal, 3, 311–322.CrossRef

34.

McAllister, S. S., Gifford, A. M., Greiner, A. L., Kelleher, S. P., Saelzler, M. P., Ince, T. A., et al. (2008). Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell, 133, 994–1005.PubMedCrossRef

35.

Nomiyama, T., Perez-Tilve, D., Ogawa, D., Gizard, F., Zhao, Y., Heywood, E. B., et al. (2007). Osteopontin mediates obesity-induced adipose tissue macrophage infiltration and insulin resistance in mice. Journal of Clinical Investigation, 117, 2877–2888.PubMedCrossRef

36.

Park, E. J., Lee, J. E., Yu, G., He, G., Ali, S. Z., Holzer, R. G., et al. (2010). Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing il-6 and tnf expression. Cell, 140, 197–208.PubMedCrossRef

37.

Philip, S., Bulbule, A., & Kundu, G. C. (2001). Osteopontin stimulates tumor growth and activation of promatrix metalloproteinase-2 through nuclear factor-kappa B-mediated induction of membrane type 1 matrix metalloproteinase in murine melanoma cells. Journal of Biological Chemistry, 276, 44926–44935.PubMedCrossRef

38.

Wai, P. Y., Mi, Z., Guo, H., Sarraf-Yazdi, S., Gao, C., Wei, J., et al. (2005). Osteopontin silencing by small interfering RNA suppresses in vitro and in vivo CT26 murine colon adenocarcinoma metastasis. Carcinogenesis, 26, 741–751.PubMedCrossRef

39.

Chen, Y. J., Wei, Y. Y., Chen, H. T., Fong, Y. C., Hsu, C. J., Tsai, C. H., et al. (2009). Osteopontin increases migration and MMP-9 up-regulation via alphavbeta3 integrin, FAK, ERK, and NF-kappa B-dependent pathway in human chondrosarcoma cells. Journal of Cell Physiology, 221, 98–108.CrossRef

40.

Das, R., Philip, S., Mahabeleshwar, G. H., Bulbule, A., & Kundu, G. C. (2005). Osteopontin: it's role in regulation of cell motility and nuclear factor kappa B-mediated urokinase type plasminogen activator expression. IUBMB Life, 57, 441–447.PubMedCrossRef

41.

Suzuki, M., Mose, E., Galloy, C., & Tarin, D. (2007). Osteopontin gene expression determines spontaneous metastatic performance of orthotopic human breast cancer xenografts. American Journal of Pathology, 171, 682–692.PubMedCrossRef

42.

Sun, B. S., Dong, Q. Z., Ye, Q. H., Sun, H. J., Jia, H. L., Zhu, X. Q., et al. (2008). Lentiviral-mediated miRNA against osteopontin suppresses tumor growth and metastasis of human hepatocellular carcinoma. Hepatology, 48, 1834–1842.PubMedCrossRef

43.

Castellano, G., Malaponte, G., Mazzarino, M. C., Figini, M., Marchese, F., Gangemi, P., et al. (2008). Activation of the osteopontin/matrix metalloproteinase-9 pathway correlates with prostate cancer progression. Clinical Cancer Research, 14, 7470–7480.PubMedCrossRef

44.

Zhang, A., Liu, Y., Shen, Y., Xu, Y., Li, X. (2009). Osteopontin silencing by small interfering RNA induces apoptosis and suppresses invasion in human renal carcinoma Caki-1 cells. Medical Oncology (in press)

45.

Song, G., Ouyang, G., Mao, Y., Ming, Y., Bao, S., Hu, T. (2008). Osteopontin promotes gastric cancer metastasis by augmenting cell survival and invasion through Akt-mediated HIF-1alpha up-regulation and MMP9 activation. Journal of Cellular and Molecular Medicine 13(8b): 1706-1718.

46.

Song, G., Cai, Q. F., Mao, Y. B., Ming, Y. L., Bao, S. D., & Ouyang, G. L. (2008). Osteopontin promotes ovarian cancer progression and cell survival and increases HIF-1alpha expression through the PI3-K/Akt pathway. Cancer Science, 99, 1901–1907.PubMed

47.

Scatena, M., Almeida, M., Chaisson, M. L., Fausto, N., Nicosia, R. F., & Giachelli, C. M. (1998). NF-kappaB mediates alphavbeta3 integrin-induced endothelial cell survival. Journal of Cellular Biological, 141, 1083–1093.CrossRef

48.

Rice, J., Courter, D. L., Giachelli, C. M., & Scatena, M. (2006). Molecular mediators of alphavbeta3-induced endothelial cell survival. Journal of Vascular Research, 43, 422–436.PubMedCrossRef

49.

Mosser, D. M., & Edwards, J. P. (2008). Exploring the full spectrum of macrophage activation. Nature Reviews Immunology, 8, 958–969.PubMedCrossRef

50.

Guo, H., Cai, C. Q., Schroeder, R. A., & Kuo, P. C. (2001). Osteopontin is a negative feedback regulator of nitric oxide synthesis in murine macrophages. Journal of Immunology, 166, 1079–1086.

51.

Wai, P. Y., Guo, L., Gao, C., Mi, Z., Guo, H., & Kuo, P. C. (2006). Osteopontin inhibits macrophage nitric oxide synthesis to enhance tumor proliferation. Surgery, 140, 132–140.PubMedCrossRef

52.

Cantor, H., & Shinohara, M. L. (2009). Regulation of T-helper-cell lineage development by osteopontin: the inside story. Nature Reviews Immunology, 9, 137–141.PubMedCrossRef

53.

Murugaiyan, G., Mittal, A., & Weiner, H. L. (2008). Increased osteopontin expression in dendritic cells amplifies IL-17 production by CD4+ T cells in experimental autoimmune encephalomyelitis and in multiple sclerosis. Journal of Immunology, 181, 7480–7488.

54.

Shinohara, M. L., Kim, J. H., Garcia, V. A., & Cantor, H. (2008). Engagement of the type I interferon receptor on dendritic cells inhibits T helper 17 cell development: role of intracellular osteopontin. Immunity, 29, 68–78.PubMedCrossRef

55.

Murugaiyan, G., & Saha, B. (2009). Protumor vs. antitumor functions of IL-17. Journal of Immunology, 183, 4169–4175.CrossRef

56.

Senger, D. R., Ledbetter, S. R., Claffey, K. P., Papadopoulos-Sergiou, A., Peruzzi, C. A., & Detmar, M. (1996). Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin. American Journal of Pathology, 149, 293–305.PubMed

57.

Dai, J., Peng, L., Fan, K., Wang, H., Wei, R., Ji, G., et al. (2009). Osteopontin induces angiogenesis through activation of PI3K/AKT and ERK1/2 in endothelial cells. Oncogene, 28, 3412–3422.PubMedCrossRef

58.

Hirama, M., Takahashi, F., Takahashi, K., Akutagawa, S., Shimizu, K., Soma, S., et al. (2003). Osteopontin overproduced by tumor cells acts as a potent angiogenic factor contributing to tumor growth. Cancer Letters, 198, 107–117.PubMedCrossRef

59.

Tang, H., Wang, J., Bai, F., Zhai, H., Gao, J., Hong, L., et al. (2008). Positive correlation of osteopontin, cyclooxygenase-2 and vascular endothelial growth factor in gastric cancer. Cancer Investigation, 26, 60–67.PubMedCrossRef

60.

Jessen, K. A., Liu, S. Y., Tepper, C. G., Karrim, J., McGoldrick, E. T., Rosner, A., et al. (2004). Molecular analysis of metastasis in a polyomavirus middle T mouse model: the role of osteopontin. Breast Cancer Research, 6, R157–R169.PubMedCrossRef

61.

Crawford, H. C., Matrisian, L. M., & Liaw, L. (1998). Distinct roles of osteopontin in host defense activity and tumor survival during squamous cell carcinoma progression in vivo. Cancer Research, 58, 5206–5215.PubMed

62.

Nemoto, H., Rittling, S. R., Yoshitake, H., Furuya, K., Amagasa, T., Tsuji, K., et al. (2001). Osteopontin deficiency reduces experimental tumor cell metastasis to bone and soft tissues. Journal of Bone and Mineral Research, 16, 652–659.PubMedCrossRef

63.

Feng, F., & Rittling, S. R. (2000). Mammary tumor development in MMTV-c-myc/MMTV-v-Ha-ras transgenic mice is unaffected by osteopontin deficiency. Breast Cancer Research and Treatment, 63, 71–79.PubMedCrossRef

64.

Ye, Q. H., Qin, L. X., Forgues, M., He, P., Kim, J. W., Peng, A. C., et al. (2003). Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nature Medicine, 9, 416–423.PubMedCrossRef

65.

Termine, J. D., Kleinman, H. K., Whitson, S. W., Conn, K. M., McGarvey, M. L., & Martin, G. R. (1981). Osteonectin, a bone-specific protein linking mineral to collagen. Cell, 26, 99–105.PubMedCrossRef

66.

Mason, I. J., Taylor, A., Williams, J. G., Sage, H., & Hogan, B. L. (1986). Evidence from molecular cloning that SPARC, a major product of mouse embryo parietal endoderm, is related to an endothelial cell 'culture shock' glycoprotein of Mr 43, 000. EMBO Journal, 5, 1465–1472.PubMed

67.

Emerson, R. O., Sage, E. H., Ghosh, J. G., & Clark, J. I. (2006). Chaperone-like activity revealed in the matricellular protein SPARC. Journal Cellular Biochemistry, 98, 701–705.CrossRef

68.

Martinek, N., Shahab, J., Saathoff, M., & Ringuette, M. (2008). Haemocyte-derived SPARC is required for collagen IV-dependent stability of basal laminae in Drosophila embryos. Journal of Cell Science, 121, 1671–1680.PubMedCrossRef

69.

Martinek, N., Shahab, J., Sodek, J., & Ringuette, M. (2007). Is SPARC an evolutionarily conserved collagen chaperone? Journal of Dental Research, 86, 296–305.PubMedCrossRef

70.

Gilmour, D. T., Lyon, G. J., Carlton, M. B., Sanes, J. R., Cunningham, J. M., Anderson, J. R., et al. (1998). Mice deficient for the secreted glycoprotein SPARC/osteonectin/BM40 develop normally but show severe age-onset cataract formation and disruption of the lens. EMBO Journal, 17, 1860–1870.PubMedCrossRef

71.

Delany, A. M., Amling, M., Priemel, M., Howe, C., Baron, R., & Canalis, E. (2000). Osteopenia and decreased bone formation in osteonectin-deficient mice. Journal of Clinical Investigation, 105, 915–923.PubMedCrossRef

72.

Bradshaw, A. D., Puolakkainen, P., Dasgupta, J., Davidson, J. M., Wight, T. N., & Helene Sage, E. (2003). SPARC-null mice display abnormalities in the dermis characterized by decreased collagen fibril diameter and reduced tensile strength. Journal of Investigative Dermatology, 120, 949–955.PubMedCrossRef

73.

Schellings, M. W., Vanhoutte, D., Swinnen, M., Cleutjens, J. P., Debets, J., van Leeuwen, R. E., et al. (2009). Absence of SPARC results in increased cardiac rupture and dysfunction after acute myocardial infarction. Journal Experimental Medicine, 206, 113–123.CrossRef

74.

McCurdy, S., Baicu, C. F., Heymans, S., & Bradshaw, A. D. (2009). Cardiac extracellular matrix remodeling: Fibrillar collagens and Secreted Protein Acidic and Rich in Cysteine (SPARC). J Mol Cell Cardiol, 48(3), 544–549.PubMedCrossRef

75.

Levental, K. R., Yu, H., Kass, L., Lakins, J. N., Egeblad, M., Erler, J. T., et al. (2009). Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell, 139, 891–906.PubMedCrossRef

76.

Bradshaw, A. D., Reed, M. J., & Sage, E. H. (2002). SPARC-null mice exhibit accelerated cutaneous wound closure. Journal of Histochemistry and Cytochemistry, 50, 1–10.PubMed

77.

Savani, R. C., Zhou, Z., Arguiri, E., Wang, S., Vu, D., Howe, C. C., et al. (2000). Bleomycin-induced pulmonary injury in mice deficient in SPARC. American Journal of Physiology-Lung Cellular and Molecular Physiology, 279, L743–L750.PubMed

78.

Sangaletti, S., Gioiosa, L., Guiducci, C., Rotta, G., Rescigno, M., Stoppacciaro, A., et al. (2005). Accelerated dendritic-cell migration and T-cell priming in SPARC-deficient mice. Journal of Cell Science, 118, 3685–3694.PubMedCrossRef

79.

Fidler IJ (2001) Seed and soil revisited: contribution of the organ microenvironment to cancer metastasis. Surg Oncol Clin N Am 10:257-269 vii-viiii

80.

Popivanova, B. K., Kitamura, K., Wu, Y., Kondo, T., Kagaya, T., Kaneko, S., et al. (2008). Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. Journal of Clinical Investigation, 118, 560–570.PubMed

81.

Thun, M. J., Namboodiri, M. M., & Heath, C. W., Jr. (1991). Aspirin use and reduced risk of fatal colon cancer. New England Journal of Medicine, 325, 1593–1596.PubMedCrossRef

82.

Kim, S., Takahashi, H., Lin, W. W., Descargues, P., Grivennikov, S., Kim, Y., et al. (2009). Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature, 457, 102–106.PubMedCrossRef

83.

Borrello, M. G., Alberti, L., Fischer, A., Degl'innocenti, D., Ferrario, C., Gariboldi, M., et al. (2005). Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene. Proceedings of the National Academy of Science USA, 102, 14825–14830.CrossRef

84.

Melani, C., Chiodoni, C., Forni, G., & Colombo, M. P. (2003). Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood, 102, 2138–2145.PubMedCrossRef

85.

Almand, B., Clark, J. I., Nikitina, E., van Beynen, J., English, N. R., Knight, S. C., et al. (2001). Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. Journal of Immunology, 166, 678–689.

86.

Melani, C., Sangaletti, S., Barazzetta, F. M., Werb, Z., & Colombo, M. P. (2007). Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Research, 67, 11438–11446.PubMedCrossRef

87.

Sangaletti, S., Stoppacciaro, A., Guiducci, C., Torrisi, M. R., & Colombo, M. P. (2003). Leukocyte, rather than tumor-produced SPARC, determines stroma and collagen type IV deposition in mammary carcinoma. Journal Experimental Medicine, 198, 1475–1485.CrossRef

88.

Bradshaw, A. D. (2009). The role of SPARC in extracellular matrix assembly. Journal Cell Commun Signal, 3(3–4), 239–246.CrossRef

89.

Said, N. A., Elmarakby, A. A., Imig, J. D., Fulton, D. J., & Motamed, K. (2008). SPARC ameliorates ovarian cancer-associated inflammation. Neoplasia, 10, 1092–1104.PubMed

90.

Arnold, S., Mira, E., Muneer, S., Korpanty, G., Beck, A. W., Holloway, S. E., et al. (2008). Forced expression of MMP9 rescues the loss of angiogenesis and abrogates metastasis of pancreatic tumors triggered by the absence of host SPARC. Experimental Biology and Medical (Maywood), 233, 860–873.CrossRef

91.

Shi, Q., Bao, S., Song, L., Wu, Q., Bigner, D. D., Hjelmeland, A. B., et al. (2007). Targeting SPARC expression decreases glioma cellular survival and invasion associated with reduced activities of FAK and ILK kinases. Oncogene, 26, 4084–4094.PubMedCrossRef

92.

Said, N., Najwer, I., & Motamed, K. (2007). Secreted protein acidic and rich in cysteine (SPARC) inhibits integrin-mediated adhesion and growth factor-dependent survival signaling in ovarian cancer. American Journal of Pathology, 170, 1054–1063.PubMedCrossRef

93.

Ng, M. R., & Brugge, J. S. (2009). A stiff blow from the stroma: collagen crosslinking drives tumor progression. Cancer Cells, 16, 455–457.CrossRef

94.

Sternlicht, M. D., Lochter, A., Sympson, C. J., Huey, B., Rougier, J. P., Gray, J. W., et al. (1999). The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. Cell, 98, 137–146.PubMedCrossRef

95.

Zaman, M. H., Trapani, L. M., Sieminski, A. L., Mackellar, D., Gong, H., Kamm, R. D., et al. (2006). Migration of tumor cells in 3D matrices is governed by matrix stiffness along with cell-matrix adhesion and proteolysis. Proceedings of the National Academy Sciences USA, 103, 10889–10894.CrossRef

96.

Lin, E. Y., Gouon-Evans, V., Nguyen, A. V., & Pollard, J. W. (2002). The macrophage growth factor CSF-1 in mammary gland development and tumor progression. Journal Mammary Gland Biology and Neoplasia, 7, 147–162.CrossRef

97.

Sangaletti, S., Di Carlo, E., Gariboldi, S., Miotti, S., Cappetti, B., Parenza, M., et al. (2008). Macrophage-derived SPARC bridges tumor cell-extracellular matrix interactions toward metastasis. Cancer Research, 68, 9050–9059.PubMedCrossRef

98.

Mantoni, T. S., Schendel, R. R., Rodel, F., Niedobitek, G., Al-Assar, O., Masamune, A., et al. (2008). Stromal SPARC expression and patient survival after chemoradiation for non-resectable pancreatic adenocarcinoma. Cancer Biol Ther, 7(11), 1806–1815.PubMed

99.

Infante, J. R., Matsubayashi, H., Sato, N., Tonascia, J., Klein, A. P., Riall, T. A., et al. (2007). Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. Journal Clinical Oncology, 25, 319–325.CrossRef

100.

Delany, A. M., & Hankenson, K. D. (2009). Thrombospondin-2 and SPARC/osteonectin are critical regulators of bone remodeling. Journal Cell Commun Signal, 3, 227–238.CrossRef

101.

Nie, J., & Sage, E. H. (2009). SPARC inhibits adipogenesis by its enhancement of beta-catenin signaling. Journal of Biology Chemistry, 284, 1279–1290.CrossRef

102.

Brown, T. J., Shaw, P. A., Karp, X., Huynh, M. H., Begley, H., & Ringuette, M. J. (1999). Activation of SPARC expression in reactive stroma associated with human epithelial ovarian cancer. Gynecologic Oncology, 75, 25–33.PubMedCrossRef

103.

Koukourakis, M. I., Giatromanolaki, A., Brekken, R. A., Sivridis, E., Gatter, K. C., Harris, A. L., et al. (2003). Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. Cancer Research, 63, 5376–5380.PubMed

104.

Alvarez, M. J., Prada, F., Salvatierra, E., Bravo, A. I., Lutzky, V. P., Carbone, C., et al. (2005). Secreted protein acidic and rich in cysteine produced by human melanoma cells modulates polymorphonuclear leukocyte recruitment and antitumor cytotoxic capacity. Cancer Research, 65, 5123–5132.PubMedCrossRef

105.

Rotta, G., Matteoli, G., Mazzini, E., Nuciforo, P., Colombo, M. P., & Rescigno, M. (2008). Contrasting roles of SPARC-related granuloma in bacterial containment and in the induction of anti-Salmonella typhimurium immunity. Journal Experimental Medicine, 205, 657–667.CrossRef

106.

Kyriakides, T. R., & Bornstein, P. (2003). Matricellular proteins as modulators of wound healing and the foreign body response. Thrombosis and Haemostasis, 90, 986–992.PubMed

107.

Weaver, M. S., Workman, G., & Sage, E. H. (2008). The copper binding domain of SPARC mediates cell survival in vitro via interaction with integrin beta1 and activation of integrin-linked kinase. Journal Biological Chemistry, 283, 22826–22837.CrossRef

108.

Byzova, T. V., Goldman, C. K., Pampori, N., Thomas, K. A., Bett, A., Shattil, S. J., et al. (2000). A mechanism for modulation of cellular responses to VEGF: activation of the integrins. Molecular Cell, 6, 851–860.PubMed

109.

De, S., Chen, J., Narizhneva, N. V., Heston, W., Brainard, J., Sage, E. H., et al. (2003). Molecular pathway for cancer metastasis to bone. Journal Biological Chemistry, 278, 39044–39050.CrossRef

110.

Eliceiri, B. P. (2001). Integrin and growth factor receptor crosstalk. Circulation Research, 89, 1104–1110.PubMedCrossRef

111.

Sturm, R. A., Satyamoorthy, K., Meier, F., Gardiner, B. B., Smit, D. J., Vaidya, B., et al. (2002). Osteonectin/SPARC induction by ectopic beta(3) integrin in human radial growth phase primary melanoma cells. Cancer Research, 62, 226–232.PubMed

112.

Ledda, M. F., Adris, S., Bravo, A. I., Kairiyama, C., Bover, L., Chernajovsky, Y., et al. (1997). Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells. Nature Medicine, 3, 171–176.PubMedCrossRef

113.

Greten, F. R., Eckmann, L., Greten, T. F., Park, J. M., Li, Z. W., Egan, L. J., et al. (2004). IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell, 118, 285–296.PubMedCrossRef

114.

Pan, M. R., Chang, H. C., Chuang, L. Y., & Hung, W. C. (2008). The nonsteroidal anti-inflammatory drug NS398 reactivates SPARC expression via promoter demethylation to attenuate invasiveness of lung cancer cells. Experimental Biology and Medical (Maywood), 233, 456–462.CrossRef

115.

Yasui, H., Adachi, M., & Imai, K. (2003). Combination of tumor necrosis factor-alpha with sulindac in human carcinoma cells in vivo. Annals of the New York Academy of Sciences, 1010, 273–277.PubMedCrossRef

116.

Bierie, B., & Moses, H. L. (2009). Transforming growth factor beta (TGF-beta) and inflammation in cancer. Cytokine Growth Factor Rev, 21(1), 49–59.PubMedCrossRef

117.

Frangogiannis, N. G. (2008). The immune system and cardiac repair. Pharmacological Research, 58, 88–111.PubMedCrossRef

118.

Francki, A., McClure, T. D., Brekken, R. A., Motamed, K., Murri, C., Wang, T., et al. (2004). SPARC regulates TGF-beta1-dependent signaling in primary glomerular mesangial cells. Journal of Cellular Biochemistry, 91, 915–925.PubMedCrossRef

119.

Delany, A. M., Kalajzic, I., Bradshaw, A. D., Sage, E. H., & Canalis, E. (2003). Osteonectin-null mutation compromises osteoblast formation, maturation, and survival. Endocrinology, 144, 2588–2596.PubMedCrossRef

120.

Kos, K., Wong, S., Tan, B., Gummesson, A., Jernas, M., Franck, N., et al. (2009). Regulation of the fibrosis and angiogenesis promoter SPARC/osteonectin in human adipose tissue by weight change, leptin, insulin, and glucose. Diabetes, 58, 1780–1788.PubMedCrossRef

121.

Schiemann, B. J., Neil, J. R., & Schiemann, W. P. (2003). SPARC inhibits epithelial cell proliferation in part through stimulation of the transforming growth factor-beta-signaling system. Molecular Biology of the Cell, 14, 3977–3988.PubMedCrossRef

122.

Said, N., Frierson, H. F., Jr., Chernauskas, D., Conaway, M., Motamed, K., & Theodorescu, D. (2009). The role of SPARC in the TRAMP model of prostate carcinogenesis and progression. Oncogene, 28, 3487–3498.PubMedCrossRef

123.

Murphy-Ullrich, J. E. (2001). The de-adhesive activity of matricellular proteins: is intermediate cell adhesion an adaptive state? Journal of Clinical Investigation, 107, 785–790.PubMedCrossRef

124.

Socha, M. J., Said, N., Dai, Y., Kwong, J., Ramalingam, P., Trieu, V., et al. (2009). Aberrant promoter methylation of SPARC in ovarian cancer. Neoplasia, 11, 126–135.PubMed

125.

Suzuki, M., Hao, C., Takahashi, T., Shigematsu, H., Shivapurkar, N., Sathyanarayana, U. G., et al. (2005). Aberrant methylation of SPARC in human lung cancers. British Journal of Cancer, 92, 942–948.PubMedCrossRef

126.

Minn, A. J., Gupta, G. P., Siegel, P. M., Bos, P. D., Shu, W., Giri, D. D., et al. (2005). Genes that mediate breast cancer metastasis to lung. Nature, 436, 518–524.PubMedCrossRef

127.

Dhanesuan, N., Sharp, J. A., Blick, T., Price, J. T., & Thompson, E. W. (2002). Doxycycline-inducible expression of SPARC/Osteonectin/BM40 in MDA-MB-231 human breast cancer cells results in growth inhibition. Breast Cancer Research and Treatment, 75, 73–85.PubMedCrossRef

128.

Koblinski, J. E., Kaplan-Singer, B. R., VanOsdol, S. J., Wu, M., Engbring, J. A., Wang, S., et al. (2005). Endogenous osteonectin/SPARC/BM-40 expression inhibits MDA-MB-231 breast cancer cell metastasis. Cancer Research, 65, 7370–7377.PubMedCrossRef

129.

Wong, S. Y., Crowley, D., Bronson, R. T., & Hynes, R. O. (2008). Analyses of the role of endogenous SPARC in mouse models of prostate and breast cancer. Clinical & Experimental Metastasis, 25, 109–118.CrossRef

130.

Delany, A. M., McMahon, D. J., Powell, J. S., Greenberg, D. A., & Kurland, E. S. (2008). Osteonectin/SPARC polymorphisms in Caucasian men with idiopathic osteoporosis. Osteoporosis International, 19, 969–978.PubMedCrossRef

131.

Ricciardelli, C., Sakko, A. J., Ween, M. P., Russell, D. L., & Horsfall, D. J. (2009). The biological role and regulation of versican levels in cancer. Cancer and Metastasis Reviews, 28, 233–245.PubMedCrossRef

132.

Ito, T., Hashimoto, Y., Tanaka, E., Kan, T., Tsunoda, S., Sato, F., et al. (2006). An inducible short-hairpin RNA vector against osteopontin reduces metastatic potential of human esophageal squamous cell carcinoma in vitro and in vivo. Clinincal Cancer Research, 12, 1308–1316.CrossRef

133.

Mi, Z., Guo, H., Russell, M. B., Liu, Y., Sullenger, B. A., & Kuo, P. C. (2009). RNA aptamer blockade of osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells. Molecular Therapy, 17, 153–161.PubMedCrossRef

Title: Matricellular proteins: from homeostasis to inflammation, cancer, and metastasis
Authors: Claudia Chiodoni
Mario P. Colombo
Sabina Sangaletti
Publication date: 01-06-2010
Publisher: Springer US
Published in: Cancer and Metastasis Reviews / Issue 2/2010
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-010-9221-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2010

TGFβ and cancer metastasis: an inflammation link

Senescent cells as a source of inflammatory factors for tumor progression

Why not treat human cancer with interleukin-1 blockade?

Preface

Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity

Hereditary ovarian cancers: from BRCA mutations to clinical management. A modern appraisal

Keynote webinar | Spotlight on antibody–drug conjugates in cancer